December 2025

Sun Pharmaceutical Industries Ltd. announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.

Ph.D / MD / MS / MDS or equivalent degree OR three years of research, teaching, design and development after MVSc / M.Pharm / M.E / M.Tech with at least one research paper in Science Citation Index Journal.

Masters / Integrated Masters in Natural or Agricultural or Pharmaceutical Sciences/ MVSc/ Animal Sciences. OR Bachelors degree in Engineering or Technology or Medicine from a recognized University.

Master Degree in Chemistry / Pharmaceutical Science from a recognized university / Institution. M.Sc. or B.Sc. degree with P.G. Diploma in Medical Radio Isotope Technology from BARC.

Matric or its equivalent from a recognized institution. Diploma in Allopathic Pharmacy from a recognized institution. 

Ph.D. degree in any area of Life Sciences. Candidates who have submitted their thesis and awaiting the awardof a Ph.D. degree may also apply.

Post graduate degree with 1st Class in Basic Biological Sciences OR Post graduate degree with 2nd Class in Basic Biological Sciences with PhD degree in relevant field.

PhD in Biological Sciences or Chemical Sciences. Structure-based design of small molecule inhibitors that target the E protein of DENV.

Responsible for coordination with various departments like Regulatory Affairs, Manufacturing, Warehouse, Quality Assurance, Quality Control, Engineering for execution of Scale-up and Exhibit batches.